logo

BLRX

BioLineRx·NASDAQ
--
--(--)
--
--(--)
6.91 / 10
Outperform

Fundamental breakdown reveals favorable profile (6.9/10). Supportive elements: PB-ROE and Asset-MV, balanced by issues in Current assets turnover ratio and Net profit / Total profit (%). This suggests favorable positioning.

Fundamental(6.91)SentimentTechnical

Analysis Checks(8/10)

Revenue-MV
Value-2.15
Score2/3
Weight18.44%
1M Return11.69%
Inventory turnover ratio
Value0.07
Score2/3
Weight-3.07%
1M Return-2.63%
Gross profit margin (%)
Value80.73
Score2/3
Weight2.00%
1M Return1.47%
Profit-MV
Value-0.78
Score3/3
Weight25.83%
1M Return12.18%
PB-ROE
Value-0.69
Score3/3
Weight19.00%
1M Return11.47%
Current assets turnover ratio
Value0.04
Score0/3
Weight-2.21%
1M Return-1.88%
Fixed assets turnover ratio
Value3.56
Score2/3
Weight0.16%
1M Return0.12%
Asset-MV
Value-0.50
Score3/3
Weight28.09%
1M Return14.99%
Cash-MV
Value-0.07
Score2/3
Weight12.12%
1M Return7.73%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight-0.36%
1M Return-0.30%
Is BLRX undervalued or overvalued?
  • BLRX scores 6.91/10 on fundamentals and holds a Discounted valuation at present. Backed by its 1.27% ROE, -23.38% net margin, -1.66 P/E ratio, 0.66 P/B ratio, and -100.00% earnings growth, these metrics solidify its Outperform investment rating.